Cervical cancer in the asian pacific - epidemiology, screening and treatment

Asian Pacific Journal of Cancer Prevention

Volumn 5, Issue 4, 2004, Pages 349-361

  Moore, Malcolm A ^a   Tajima, Kazuo ^b  

^a APOCP Coordination and Training Center   (Thailand)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Analytical epidemiology; Descriptive epidemiology; Risk factors; Screening; Vaccine

Indexed keywords

CANCER VACCINE;

ASIA; AUSTRALIA; FEMALE; HUMAN; INCIDENCE; MASS SCREENING; PACIFIC ISLANDS; REVIEW; RISK FACTOR; UTERINE CERVIX TUMOR;

ASIA; AUSTRALIA; CANCER VACCINES; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; PACIFIC ISLANDS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 16644367871     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Acladious NN, Sutton C, Mandal D, et al (2002). Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer, 98, 435-9.
2. Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ (2004). Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care, 42, 600-9.
3. Ahn Y-O (2001). Population-nased cancer registries in Korea. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 39-42.
4. Anh PH (2001). Cancer registration in Vietnam. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 85-9.
5. Anh PTH, Hieu NT, Herrero R, et al (2003). Human papillomavirus infection among women in South and North Vietnam. Int J Cancer, 104, 213-20.
6. Al Hamdan N, Bazarbashi S, Ajarim D, et al (2001). Cancer registration in Saudi Arabia. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 61-4.
7. al-Lawati JA, al-Shaqsi, B N al-Siyabi (2001).Cancer registration in the Sultanate of Oman. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 71-4.
8. Anttila A, Ronco G, Clifford G, et al (2004). Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer, 91, 935-41.
9. Ault KA, Giuliano AR, Edwards RP, et al (2004). A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine, 22, 3004-7.
10. Basu PS, Sankaranarayanan R, Mandal R, et al (2003) Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. Int J Gynecol Cancer, 13, 626-32.
11. Bell MC, Crowley-Nowick P, Bradlow HL, et al (2000). Placebocontrolled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol, 78, 123-9.
12. Berrington de Gonzalez A, Sweetland S, Green J (2004). Comparison of risk factors for squamous cell and adenocarcinomas of the cervix: a meta-analysis. Br J Cancer, 90,1787-91.
13. Bhatla N, Mukhopadhyay A, Joshi S, et al (2004). Visual inspection for cervical cancer screening: evaluation by doctor versus paramedical worker. Indian J Cancer, 41, 32-6.
14. Bhurgri Y (2001). Cancer registration in Pakistan. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 51-4.
15. Castle PE, Hillier SL, Rabe LK, et al (2001). An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev, 10, 1021-7.
16. Cecchini S, Carozzi F, Confortini M, Zappa M, Ciatto S (2004). Persistent human papilloma virus infection as an indicator of risk of recurrence of high-grade cervical intraepithelial neoplasia treated by the loop electrosurgical excision procedure. Tumori, 90, 225-8.
17. Cheung AN, Szeto EF, Leung BS, Khoo US, Ng AW (2003). Liquidbased cytology and conventional cervical smears: a comparison study in an Asian screening population. Cancer, 99, 331-5.
18. Cheung AN, Szeto EF, Ng KM, et al (2004). Atypical squamous cells of undetermined significance on cervical smears: followup study of an Asian screening population. Cancer, 102, 74-80.
19. Chirenje ZM, Chipato T, Kasule J, Rusakaniko S (1999). Visual inspection of the cervix as a primary means of cervical cancer screening: results of a pilot study. Cent Afr J Med, 45, 30-3.
20. Clavel C, Masure M, Bory JP, et al (2001). Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer, 84, 1616-23.
21. Costa S, Sideri M, Syrjanen K, et al (2000). Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytol, 44, 310-8.
22. Crum CP, Abbott DW, Quade BJ (2003). Cervical cancer screening: from the Papanicolaou smear to the vaccine era. J Clin Oncol, 21 (10 Suppl), 224-30.
23. Crum CP, Beach KJ, Hedley ML, et al (2004). Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J Infect Dis, 189, 1348-54.
24. Deerasamee S, Martin N, Sontipong S, et al (2001). Cancer registration in Thailand. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 79-84.
25. DiPaolo JA, Popescu NC, Woodworth CD, Zimonjic DB (1996). Papillomaviruses and potential copathogens. Toxicol Lett, 88, 1-7.
26. Duttagupta C, Sengupta S, Roy M, et al (2004). Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India. Int J Gynecol Cancer, 14, 293-303.
27. Dzuba IG, Diaz EY, Allen B, et al (2002). The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med, 11, 265-75.
28. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J (2002). Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol, 100, 965-71.
29. Esteban DB, Laudico AV, Uy NA, Benabay L (2001). Cancer registration in the Philippines. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 55-60.
30. Farley J, Uyehara C, Hashiro G, et al (2004). Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol, 92, 596-602.
31. Fidaner C, Eser SY, Parkin DM (2001). Incidence in Izmir in 1993-1994: first results from Izmir Cancer Registry. Eur J Cancer, 37, 83-92.
32. Follen M, Vlastos AT, Meyskens FL Jr, Atkinson EN, Schottenfeld D (2002).Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control, 13, 855-73.
33. Franceschi S, Clifford G, Plummer M (2003). Prospects for primary prevention of cervical cancer in developing countries. Salud Publica Mex, 45 Suppl 3, S430-6.
34. Franco EL (2004). Randomized controlled trials of HPV testing and Pap cytology: toward evidence-based cervical cancer prevention. Int J Cancer, 110, 1-2.
35. Gaiotto MA, Focchi J, Ribalta JL, et al (2004). Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. Am J Obstet Gynecol, 190, 1278-82.
36. Gajalakshmi V, Rajaraman S, Shanta V (2000). A survival study of cervical cancer in Chennai, India. Indian J Cancer, 37, 158-64.
37. Gajalakshmi V, Shantha V, Swaminathan R (2001). Cancer registration in India. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 13-20.
38. Ganguly C, Dutta K, Sanyal U, et al (2001). Response of cervical intra-epithelial lesions to vitamin E supplementation - a preliminary report. Asian Pacific J Cancer Prev, 2, 305-8.
39. Ghaemmaghami F, Behtash N, Modares Gilani M, et al (2004). Visual inspection with acetic acid as a feasible screening test for cervical neoplasia in Iran. Int J Gynecol Cancer, 14, 465-9.
40. Ghim S-J, Basu PS, Jenson AB (2002) Cervical cancer: etiology, pathogenesis, treatment, and future vaccines. Asian Pacific J Cancer Prev, 3, 207-14.
41. Giuliano AR, Harris R, Sedjo RL, et al (2002). Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis, 186, 462-9.
42. Giuliano AR, Papenfuss M, Abrahamsen M, Inserra P (2002). Differences in factors associated with oncogenic and nononcogenic human papillomavirus infection at the United States-Mexico border. Cancer Epidemiol Biomarkers Prev, 11, 930-4.
43. Giuliano AR, Papenfuss M, Nour M, et al (1997). Antioxidant nutrients: associations with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev, 6, 917-23.
44. Giuliano AR, Sedjo RL, Roe DJ, et al (2002). Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes Control, 13, 839-46.
45. Gonzalez-Sanchez JL, Martinez-Chequer JC, Hernandez-Celaya ME, Barahona-Bustillos E, Andrade-Manzano AF (2001). Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus. Obstet Gynecol, 97, 621-4.
46. Goodman MT, Kiviat N, McDuffie K, et al (1998). The association of plasma micronutrients with the risk of cervical dysplasia in Hawaii. Cancer Epidemiol Biomarkers Prev, 7, 537-44.
47. Goodman MT, McDuffie K, Hernandez B, et al (2000).The association of plasma micronutrients with the risk of cervical Atypical Squamous Cells of Undetermined Significance (ASCUS). Asian Pacific J Cancer Prev, 1, 339-47.
48. Gravitt PE, Lacey JV Jr, Brinton LA, et al (2001). Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev, 10, 95-100.
49. Green J, Berrington De, Gonzalez A, et al (2003). Human papillomavirus infection and use of oral contraceptives. Br J Cancer, 88, 1713-20.
50. Gudmundsdottir T, Tryggvadottir L, Allende M, et al (2003). Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand, 82, 345-50.
51. Harris TG, Kulasingam SL, Kiviat NB, et al (2004). Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol, 159, 834-42.
52. Hengge UR, Benninghoff B, Ruzicka T, Goos M (2001). Topical immunomodulators--progress towards treating inflammation, infection, and cancer. Lancet Infect Dis, 1, 189-98.
53. Ho GY, Palan PR, Basu J, et al (1998). Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer, 78, 594-9.
54. Hoover DR, Carfioli B, Moench EA (2000). Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int, 21, 375-91.
55. Hopfl R, Heim K, Christensen N, et al (2000). Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet, 356, 1985-6.
56. Hou SI, Fernandez ME, Parcel GS (2004). Development of a cervical cancer educational program for Chinese women using intervention mapping. Health Promot Pract, 5, 80-7.
57. Hudelist G, Manavi M, Pischinger KI, et al (2004). Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol, 92, 873-80.
58. Ishi K, Suzuki F, Saito A, Kubota T (2000). Prevalence of human papillomavirus infection and its correlation with cervical lesions in commercial-sex workers in Japan. J Obstet Gynaecol Res, 26, 253-7.
59. Islam S, West AM, Saboorian MH, Ashfaq R (2004). Reprocessing unsatisfactory ThinPrep Papanicolaou test specimens increases sample adequacy and detection of significant cervicovaginal lesions. Cancer, 102, 67-73.
60. Jayant K, Rao RS, Nene BM, Dale PS, Nandakumar A (1996). Improved survival in cervical cancer cases in a rural Indian population. Br J Cancer, 74, 285-7.
61. Juarez-Figueroa LA, Wheeler CM, Uribe-Salas FJ, et al (2001). Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sex Transm Dis, 28, 125-30.
62. Kadish AS, Timmins P, Wang Y, et al (2002). Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cellmediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev, 11, 483-8.
63. Kanetsky PA, Gammon MD, Mandelblatt J, et al (1998). Dietary intake and blood levels of lycopene: association with cervical dysplasia among non-Hispanic, black women. Nutr Cancer, 31, 31-40.
64. Kawana K, Yasugi T, Kanda T, et al (2002). Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun, 296, 102-5.
65. Keefe KA, Schell MJ, Brewer C, et al (2001). A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 10, 1029-35.
66. Kim JW, Hung CF, Juang J, et al (2004). Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther, 11, 1011-8.
67. Kjaer SK, van den Brule AJ, et al (2002). Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ, 325, 572.
68. Koutsky LA, Ault KA, Wheeler CM, et al (2002). A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 347, 1645-51.
69. Kruse AJ, Baak JP, Janssen EA, et al (2003). Low- and high-risk CIN 1 and 2 lesions: prospective predictive value of grade, HPV, and Ki-67 immuno-quantitative variables. J Pathol, 199, 462-70.
70. Kulmala SM, Syrjanen S, Shabalova I, et al (2004). Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol, 42, 2470-5.
71. Kumaraswamy, Nandakumar A, Venugopal T, Viswanathan N (1998). Survival in cancer of the cervix: treatment in a population-based cancer registry in a developing country (Bangalore, India). Cancer Causes Control, 9, 117-23.
72. Lazcano-Ponce E, Rivera L, et al (2001). Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res, 32, 243-7.
73. Lea JS, Coleman R, Kurien A, et al (2004).Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol, 190, 674-9.
74. Lee KJ, Lee JK, Saw HS (2004). Can human papillomavirus DNA testing substitute for cytology in the detection of high-grade cervical lesions? Arch Pathol Lab Med, 128, 298-302.
75. Lehtinen M, Koskela P, Jellum E, et al (2002). Herpes simplex virus and risk of cervical cancer: a longitudinal, nested casecontrol study in the nordic countries. Am J Epidemiol, 156, 687-92.
76. Livasy CA, Moore DT, Van Le L (2004).The clinical significance of a negative loop electrosurgical cone biopsy for high-grade dysplasia. Obstet Gynecol, 104, 250-4.
77. Longworth MS, Laimins LA (2004). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev, 68, 362-72.
78. Mak R, Van Renterghem L, Cuvelier C (2004). Cervical smears and human papillomavirus typing in sex workers. Sex Transm Infect, 80, 118-20.
79. Mandic A, Vujkov T (2004). Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol, 15, 197-200
80. Markovic O, Markovic N (2003-2004). Cervical acid phosphatase: a biomarker of cervical dysplasia and a potential surrogate endpoint for colposcopy. Dis Markers, 19, 279-86.
81. Mitchell H, Hocking J, Saville M (2003). Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer, 99, 336-41.
82. Mitchell MF, Hittelman WN, Lotan R, et al (1995). Chemoprevention trials in the cervix: design, feasibility, and recruitment. J Cell Biochem Suppl, 23, 104-12.
83. Moore MA, Kunimoto T, Tsuda H (2003). Cancer screening literature in the period 2000-2002; pointers to future research avenues. Asian Pacific J Cancer Prev, 4, 57-60.
84. Moore MA, Tajima K, Anh PH, et al (2003). Grand challenges in global health and the Practical Prevention Program? Asian focus on cancer prevention in females of the developing world. Asian Pacific J Cancer Prev, 4, 153-65.
85. Moreno V, Bosch FX, Munoz N, et al (2002). Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet, 359, 1085-92.
86. Mosavi-Jarrahi A, Mohagheghi MA, Zeraatti H, Mortazavi H (2001). Cancer registration in Iran. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 25-9.
87. Mount S, Harmon M, Eltabbakh G, Uyar D, Leiman G (2004). False positive diagnosis in conventional and liquid-based cervical specimens. Acta Cytol, 48, 363-71.
88. Muir CS, Waterhouse J, Mack T, Powell J, Whelan SL (Eds) (1987). Cancer Incidence in Five Continents Vol. V. IARC Scientific Publications No 88. IARC, Lyon.
89. Munkhtaivan A, Erdentuya S, Ozzi-Delger T (2001). Cancer registration in Mongolia. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 47-50.
90. Munoz N, Bosch FX, Castellsague X, et al (2004). Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer, 111, 278-85.
91. Munoz N, Franceschi S, Bosetti C, et al (2002). Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet, 359, 1093-101.
92. Nagai N, Mukai K, Oshita T, Shiroyama Y, Ohama K (2004). Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III - A prospective study. Int J Mol Med, 13, 589-93.
93. Nakao Y, Yang X, Yokoyama M, Pater MM, Pater A (1996). Malignant transformation of human ectocervical cells immortalized by HPV 18: in vitro model of carcinogenesis by cigarette smoke. Carcinogenesis, 17, 577-83.
94. National Cancer Institute Workshop (1989). The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnoses. JAMA, 262, 931-4.
95. National Cancer Institute Workshop (1993). The Bethesda system for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, 1991. Acta Cytol, 37, 115-124.
96. Ng KY, Chang CK, Chen J, Wang PH, Teng SW (2004). Is direct large loop electric excision for the transformation zone reasonable in the investigation of high-grade squamous intraepithelial lesions in cervical smears? Eur J Gynaecol Oncol, 25, 61-5.
97. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A (2004). Comparison of HPV test versus conventional and automationassisted Pap screening as potential screening tools for preventing cervical cancer. BJOG, 111, 842-8.
98. O'Brien ED, Bailie RS, Jelfs PL (2000). Cervical cancer mortality in Australia: contrasting risk by Aboriginality, age and rurality. Int J Epidemiol, 29, 813-6.
99. Ohshima A, Tsukuma H, Ajiki W, for the Research group for Cancer Registration in Japan (2001). Cancer registration in Japan. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 31-6.
100. Ozkan F, Ramzy I, Mody DR (2004). Glandular lesions of the cervix on thin-layer Pap tests. Validity of cytologic criteria used in identifying significant lesions. Acta Cytol, 48, 372-9.
101. Palan PR, Woodall AL, Anderson PS, Mikhail MS (2004). Alphatocopherol and alpha-tocopheryl quinone levels in cervical intraepithelial neoplasia and cervical cancer. Am J Obstet Gynecol, 190, 1407-10.
102. Paraskevaidis E, Arbyn M, Sotiriadis A, et al (2004) The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev, 30, 205-11.
103. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J (Eds) (1992). Cancer Incidence in Five Continents Vol. VI. IARC Scientific Publications No 120. IARC, Lyon.
104. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (Eds) (1997). Cancer Incidence in Five Continents Vol. VII. IARC Scientific Publications No 143. IARC, Lyon.
105. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (Eds) (2002). Cancer Incidence in Five Continents Vol. VIII. IARC Scientific Publications No 155. IARC, Lyon.
106. Pengsaa P, Vatanasapt V, Sriamporn S, et al (1997). A selfadministered device for cervical cancer screening in northeast Thailand. Acta Cytol, 41, 749-54.
107. Plummer M, Herrero R, Franceschi S, et al (2003) Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control, 14, 805-14.
108. Qasem MB (2001). Cancer registration in Jordan. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 37-8.
109. Renshaw AA, Mody DR, Lozano RL, et al (2004). Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. Arch Pathol Lab Med, 128, 153-7.
110. Richart RM (1968). Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol, 5, 748-84.
111. Richart RM (1968). A modified terminology for cervical intraepithelial neoplasia. Obstet Gynecol, 75, 113-3.
112. Risi L, Bindman JP, Campbell OM, et al (2004). Media interventions to increase cervical screening uptake in South Africa: an evaluation study of effectiveness. Health Educ Res, 19, 457-68.
113. Roden RB, Ling M, Wu TC (2004). Vaccination to prevent and treat cervical cancer. Hum Pathol, 35, 971-82.
114. Rosemawati A, Sallehudin AB (2001). Cancer registration in Malaysia. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 43-5.
115. Sahebali S, Depuydt CE, Segers K, et al (2004). P16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer, 108, 871-6.
116. Sanchaisuriya P, Pengsaa P, Sriamporn S, et al (2004) Experience with a self-administered device for cervical cancer screening by Thai women with different educational backgrounds. Asian Pac J Cancer Prev, 5, 144-50.
117. Sankaranarayanan R, Basu P, Wesley RS, et al (2004). Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer, 110, 907-13.
118. Sankaranarayanan R, Nair MK, Jayaprakash PG, et al (1995). Cervical cancer in Kerala: a hospital registry-based study on survival and prognostic factors. Br J Cancer, 72, 1039-42.
119. Sankaranarayanan R, Rajkumar R, Theresa R, et al (2004). Initial results from a randomized trial of cervical visual screening in rural south India. Int J Cancer, 109, 461-7.
120. Sankaranaraynan R, Wesley R, Somanthanan T, et al (1998). Visual inspection of the uterine cervix after the application of acetic acid in the detection of cervical carcinoma and its precursors. Cancer, 83, 2150-6.
121. Sarian LO, Derchain SF, Andrade LA, et al (2004). HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol Oncol, 94,181-6.
122. Sarjadi, Trihartani P (2001). Cancer registration in Indonesia. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 21-4.
123. Sass MA (2004). Use of a liquid-based, thin-layer Pap test in a community hospital. Impact on cytology performance and productivity. Acta Cytol, 48, 17-22.
124. Schiffman M, Wheeler CM, Castle PE (2002). Atypical Squamous cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study Group. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J Infect Dis, 186, 1169-72.
125. Schiller CL, Nickolov AG, Kaul KL, et al (2004). High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization. Am J Clin Pathol, 121, 537-45.
126. Schorge JO, Lea JS, Elias KJ, et al (2004). P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol, 190, 668-73.
127. Schreckenberger C, Kaufmann AM (2004). Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol, 16, 485-91.
128. Sedjo RL, Inserra P, Abrahamsen M, et al (2002). Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women. Cancer Epidemiol Biomarkers Prev, 11, 353-9.
129. Sellors JW, Karwalajtys TL, Kaczorowski J, et al (2003). Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ, 168, 421-5.
130. Sellors JW, Sankarananyan R (2003). Colposcopy and Treatment of Cervical Intraepithelial Neoplasia: A Beginners' Manual. IARC Press, Lyon.
131. Sgambato A, Zannoni GF, Faraglia B, et al (2004). Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol Oncol, 92, 776-83.
132. Shannon J, Thomas DB, Ray RM, et al (2002). Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control, 13, 691-9.
133. Shin HR, Lee DH, Herrero R, et al (2003). Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer, 103, 413-21.
134. Singh V, Sehgal A, Parashari A, Sodhani P, Satyanarayana L (2001). Early detection of cervical cancer through acetic acid application--an aided visual inspection. Singapore Med J, 42, 351-4.
135. Smith JS, Bosetti C, Munoz N, et al (2004). Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer, 111, 431-9.
136. Smith JS, Herrero R, Bosetti C, et al (2002). Herpes simplex virus-2 as a human papillomavirus co-factor in the etiology of invasive cervical cancer. J Natl Cancer Inst, 94, 1604-13.
137. Smith JS, Munoz N, Herrero R, et al (2002). Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J Infect Dis, 185, 324-31.
138. Snoeck R, Andrei G, De Clercq E (2001). Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg, 63, 93-120, discussion 120-2.
139. Sriamporn S, Swaminathan R, Parkin DM, Kamsa-ard S, Hakama M (2004). Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast Thailand. Br J Cancer, 91, 106-10.
140. Suh-Burgmann E, Sivret J, Duska LR, Del Carmen M, Seiden MV (2003). Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest, 55, 25-31.
141. Tajima K, Moore MA (2001). Risk and beneficial factors - fallacy at the individual but not the population level? Relevance to a Practical Prevention Program. Asian Pacific J Cancer Prev, 2, 83-7.
142. Tanaka H, Sato H, Sato N, et al (2004). Adding HPV16 testing to abnormal cervical smear detection is useful for predicting CIN3: a prospective study. Acta Obstet Gynecol Scand, 83, 497-500.
143. Tay SK, Tay KJ (2004). Passive cigarette smoking is a risk factor in cervical neoplasia. Gynecol Oncol, 93, 116-20.
144. Taylor R, Bell J, Coates M, Churches T, Wain G (1996). Cervical cancer in New South Wales women: five-year survival, 1972 to 1991. Aust N Z J Public Health, 20, 413-20.
145. Thomas DB, Ray RM, Koetsawang A, et al (2001). Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol, 153, 723-31.
146. Thomas DB, Ray RM, Kuypers J, et al (2001). Human papillomaviruses and cervical cancer in Bangkok. III. The role of husbands and commercial sex workers. Am J Epidemiol, 153, 740-8.
147. Tran-Thanh D, Provencher D, Koushik A, et al (2003). Herpes simplex virus type II is not a cofactor to human papillomavirus in uterine cervix cancer. Am J Obstet Gynecol, 188, 129-34.
148. Tringler B, Gup CJ, Singh M, et al (2004). Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol, 35, 689-96.
149. Türkistanli{dotless} EC, Sogukpi{dotless}nar N, Saydam BK, Aydemir G (2003). Cervical cancer prevention and early detection; the role of nurse and midwives. Asian Pacific J Cancer Prev, 4, 39-44.
150. Unger JB, Ivy JJ, Connor P, et al (2004). Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol, 94, 212-6.
151. van Duin M, Snijders PJ, Schrijnemakers HF, et al (2002). Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer, 98, 590-5.
152. Velema JP, Ferrera A, Figueroa M, et al (2002). Burning wood in the kitchen increases the risk of cervical neoplasia in HPVinfected women in Honduras. Int J Cancer, 97, 536-41.
153. Wang Q (2001). Cancer registration in China. Asian Pacific J Cancer Prev, 2 (IACR Suppl), 3-8.
154. Waterhouse J, Muir C, Shanmugaratnam K, Powell J (Eds) (1982). Cancer Incidence in Five Continents Vol. IV. IARC Scientific Publications No 42. IARC, Lyon.
155. Wentzensen N, Vinokurova S, von Knebel-Doeberitz M (2004). Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res, 64, 3878-84.
156. Wesley R, Sankaranarayanan R, Mathew B, et al (1997). Evaluation of visual inspection as a screening test for cervical cancer. Br J Cancer, 75, 436-40.
157. Waller J, McCaffery KJ, Forrest S, Wardle J (2004). Human papillomavirus and cervical cancer: issues for biobehavioral and psychosocial research. Ann Behav Med, 27, 68-79.
158. Wu MT, Lee LH, Ho CK, et al (2003). Lifetime exposure to environmental tobacco smoke and cervical intraepithelial neoplasms among nonsmoking Taiwanese women. Arch Environ Health, 58, 353-9.
159. Yoshida T, Fukuda T, Sano T, et al (2004).Usefulness of liquidbased cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer, 102, 100-8.
160. Zappa M, Visioli CB, Ciatto S, et al (2004). Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer, 90, 1784-6.
161. zur Hausen H (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2, 342-50.